Neoprobe tests radiotracer in melanoma trial:
This article was originally published in Clinica
Executive Summary
Neoprobe is to begin a US clinical trial of its investigational lymphatic radiotracer in melanoma patients. The study, supported by a $250,000 grant from the American Cancer Society, will evaluate use of the agent Tc-mannosyl-dextran as a means of identifying the sentinel lymph node in patients with the disease. The accurate determination of the spread of disease into the lymphatic system is important in establishing the appropriate type of treatment, says the Dublin, Ohio firm. A study assessing use of the agent in the treatment of breast cancer is already underway in the US.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.